Spanish Biotech gets New Milestone in Biosimilar Race with Amgen

05/07/2016 - 2 minutes

The Spanish Cinfa Biotech’s race to compete with Amgen’s blockbuster for Chemotherapy-induced Neutropenia continues: the Neulasta biosimilar passes Phase I trials.

Cinfa biosimilar neutropenia cancer chemo biotechNeulasta (pegfilgrastim) is a slightly longer acting version of Amgen’s other blockbuster Neupogen (the template for the first ever US approved biosimilar – from Novartis), the combined sales of which account for over 30% of Amgen’s income.

Used to treat Neutropenia (a result of chemo) for various cancers, Neulasta’s annual sales alone are worth around €3.5Bn. It is therefore understandable other biotechs, including Cinfa, seek to take a slice of Amgen’s market corner as soon as their patent expires.

Chemotherapy-Induced neutropenia can very serious for Cancer patients, as it leaves them vulnerable to life-threatening (yet normally very mild) infections.

Cinfa’s Biosimilar (B12019) is a pegylated granulocyte colony-stimulating factor (G-CSF) receptor agonist, which is used to stimulate the patients bone marrow to produce more neutrophils.

This Phase I trial’s primary endpoint looked to compare PD and PK of Cinfa’s biosimilar (B12019) to Neulasta,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member